Figure S1. Overall survival rate of patients with non-small cell lung carcinoma based on glucose transporter1 (GLUT1) and pyruvate kinase M2 (PKM2) with GSE 42127 dataset from PROGgeneV2. (A) Relationship between overall survival rate and SLC2A1 (GLUT1 coding gene) expression. (B) Relationship between overall survival rate and PKM2 expression. GLUT1, glucose transporter 1; PKM2, pyruvate kinase M2.




Figure S2. Overall and disease-free survival rates of patients with stage II-III NSCLC based on adjuvant chemotherapy. (A) Relationship between overall survival rate and adjuvant chemotherapy in patients with GLUT1 positive NSCLC. (B) Relationship between overall survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (C) Relationship between overall survival rate and adjuvant chemotherapy in patients with of GLUT1 and PKM2 positive NSCLC. (D) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with GLUT1 positive NSCLC. (E) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (E) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (F) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (G) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (E) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (G) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (E) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with PKM2 positive NSCLC. (F) Relationship between disease-free survival rate and adjuvant chemotherapy in patients with both GLUT1 and PKM2 positive NSCLC. GLUT1, glucose transporter1; PKM2, pyruvate kinase M2; NSCLC, non-small cell lung carcinoma.




Figure S3. Overall and disease-free survival rates of patients with non-small cell lung carcinoma based on the combination of GLUT1 and PKM2 expression. (A) Relationship between overall survival rate and the combination of GLUT1 and PKM2 expression. (B) Relationship between disease-free survival rate and the combination of GLUT1 and PKM2 expression. *P<0.05. GLUT1, glucose transporter 1; PKM2, pyruvate kinase M2; G+/P+, patients with GLUT1 positive and PKM2 positive expression; G+/P-, patients with GLUT1 positive and PKM2 negative expression, G-/P+: patients with GLUT1 negative and PKM2 positive expression; G-/P-, patients with GLUT1 negative and PKM2 negative expression.

